Literature DB >> 24681111

Psychometric properties of the Polish version of the Multidimensional Fatigue Inventory-20 in cancer patients.

Tomasz Buss1, Agnieszka Kruk2, Piotr Wiśniewski3, Aleksandra Modlinska4, Justyna Janiszewska4, Monika Lichodziejewska-Niemierko4.   

Abstract

CONTEXT: Multidimensional questionnaires estimating cancer-related fatigue (CRF) as a symptom cluster or a clinical syndrome primarily have been used and validated in English-speaking populations. However, cultural issues and language peculiarities can affect CRF assessment
OBJECTIVES: The main aims of this study were to evaluate the psychometric properties of the Polish version of the Multidimensional Fatigue Inventory-20 (MFI-20) and to deliver to clinicians a multidimensional tool for CRF assessment in Polish-speaking patients with cancer.
METHODS: After forward-backward translation procedures, the Polish version of MFI-20 was administered to 340 cancer patients. The Polish MFI-20 was appraised in terms of acceptability, reliability, and validity. Internal consistency was assessed by calculating Cronbach's alpha coefficients. Structural validity was evaluated with confirmatory factor analysis.
RESULTS: The translated MFI-20 was well accepted; 90% of subjects fully completed the questionnaire. The overall Cronbach's alpha coefficient was 0.9, ranging from 0.57 to 0.81. All correlation coefficients among Numeric Rating Scale-fatigue, fatigue-related items from the European Organization for Research and Treatment of Cancer Quality of Life Core-30 questionnaire, and the MFI--20 were statistically significant (P < 0.001). Confirmatory factor analysis demonstrated good structural validity and revealed only three dimensions in the Polish version of the MFI-20-physical and mental fatigue as well as reduced motivation.
CONCLUSION: The Polish version of the MFI-20 is well accepted by patients, reliable, and a valid instrument to assess CRF in Polish cancer patients.
Copyright © 2014 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fatigue; Multidimensional Fatigue Inventory; cancer; reliability; validity

Mesh:

Year:  2014        PMID: 24681111     DOI: 10.1016/j.jpainsymman.2013.11.015

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  6 in total

1.  Fatigue in chronically critically ill patients following intensive care - reliability and validity of the multidimensional fatigue inventory (MFI-20).

Authors:  Gloria-Beatrice Wintermann; Jenny Rosendahl; Kerstin Weidner; Bernhard Strauß; Andreas Hinz; Katja Petrowski
Journal:  Health Qual Life Outcomes       Date:  2018-02-20       Impact factor: 3.186

2.  The reliability and validity of The Turkish version of Multidimensional Fatigue Inventory-20 for the evaluation of different dimensions of fatigue in patients with fibromyalgia.

Authors:  Fatma Başoğlu; Julide Öncü; Banu Kuran; Hasan Kerem Alptekin
Journal:  Turk J Phys Med Rehabil       Date:  2020-06-24

3.  Application of the Multidimensional Fatigue Inventory to Ethiopian Cancer Patients.

Authors:  Yemataw Wondie; Andreas Hinz
Journal:  Front Psychol       Date:  2021-12-02

4.  Screening and Assessment of Cancer-Related Fatigue: A Clinical Practice Guideline for Health Care Providers.

Authors:  Mary Insana Fisher; Joy C Cohn; Shana E Harrington; Jeanette Q Lee; Daniel Malone
Journal:  Phys Ther       Date:  2022-09-04

5.  Validity and reliability of the Traditional Chinese version of the Multidimensional Fatigue Inventory in general population.

Authors:  Li-Ling Chuang; Yu-Fen Chuang; Miao-Ju Hsu; Ying-Zu Huang; Alice M K Wong; Ya-Ju Chang
Journal:  PLoS One       Date:  2018-05-10       Impact factor: 3.240

6.  Fatigue in cancer patients: comparison with the general population and prognostic factors.

Authors:  Andreas Hinz; Joachim Weis; Elmar Brähler; Martin Härter; Kristina Geue; Jochen Ernst
Journal:  Support Care Cancer       Date:  2020-01-17       Impact factor: 3.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.